Clinical trial · Interventional
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Canfosfamide HCl for injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Mantle Cell Lymphoma
- description
- Patients with relapsed or refractory mantle cell lymphoma
- interventionNames
- Drug: Canfosfamide HCl for injection
- type
- EXPERIMENTAL
- label
- Diffuse Large B Cell Lymphoma
- description
- Patients with relapsed or refractory diffuse large B cell lymphoma
- interventionNames
- Drug: Canfosfamide HCl for injection
- type
- EXPERIMENTAL
- label
- Multiple Myeloma
- description
- Patients with relapsed or refractory multiple myeloma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * relapsed or refractory disease * histologically or cytologically confirmed disease * characteristic immunophenotypic profiles * measurable disease (for lymphoma patients) * ECOG performance status of 0-2 * adequate liver and kidney function * adequate bone marrow reserves * ineligible or unwilling to undergo autologous stem cell transplantation Exclusion Criteria: * failure to recover from any major surgery within 4 weeks of study entry * pregnant or lactating women * women of child-bearing potential not using reliable and appropriate contraception * routine prophylactic use of G-CSF required within 2 weeks of study entry * Grade 3 or higher peripheral neuropathy * history of hepatitis B virus or HIV * central nervous system or meningeal involvement by lymphoma or multiple myeloma
References
Publications (0)
Data not yet available